Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer

•TP53 is the most frequently mutated gene in head and neck cancers.•The prevalence of NTRK aberrations in Chinese head and neck cancers was 7.9%.•NTRK aberrations are more common in this Chinese population.•The most common fusion was ETV6-NTRK3.•Patients with NTRK fusion may benefit from targeted th...

Full description

Saved in:
Bibliographic Details
Published in:Oral oncology 2021-08, Vol.119, p.105369-105369, Article 105369
Main Authors: Xu, Jiali, Wang, Rong, Wang, Tongshan, Wang, Tingting, Gu, Dejian, He, Yuange, Shu, Yongqian, Chen, Rongrong, Liu, Lianke
Format: Article
Language:English
Subjects:
China - epidemiology
Crizotinib
DNA Fingerprinting
ETV6-NTRK3
Head and neck cancer
Head and Neck Neoplasms - epidemiology
Head and Neck Neoplasms - genetics
Humans
NTRK
NTRK inhibitor
Prevalence
Receptor, trkA - genetics
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•TP53 is the most frequently mutated gene in head and neck cancers.•The prevalence of NTRK aberrations in Chinese head and neck cancers was 7.9%.•NTRK aberrations are more common in this Chinese population.•The most common fusion was ETV6-NTRK3.•Patients with NTRK fusion may benefit from targeted therapy of NTRK inhibitors. Head and neck cancers are aggressive epithelial tumours that are recognised as being particularly challenging to treat. Here, we report the targeted DNA profiling and the prevalence of neurotrophic-tropomyosin receptor tyrosine kinase gene (NTRK) aberrations in Chinese patients with head and neck cancers. Samples of 127 patients with head and neck cancer were retrospectively analysed. Profiling was performed by next-generation sequencing of the 1021-gene panel with tumour tissue and matched peripheral blood control samples. This study was inspired by the outcome benefit of a parotid cancer patient harbouring ETV6-NTRK3 fusion, who received crizotinib treatment and achieved a 2-year progression-free survival. Genomic profiling of 127 patients with head and neck cancers indicated that TP53 is the most frequently mutated gene both in our cohort and in The Cancer Genome Atlas (TCGA) database. A higher prevalence of NTRK genetic aberrations (7.9%, 10/127), including NTRK fusion (3.1%) and mutation, was observed in our population than in TCGA. The most common fusion was the ETV6-NTRK3. Compared to the NTRK-wt group, the NTRK aberration group had more APC and PTPRD aberrations (p 
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2021.105369